clinical trial · NCT07374419
Atamparib in Patients With Advanced Solid Tumors
Nerviano Medical Sciences (Shanghai) Ltd.·phase2·not yet recruiting·n = 178
NSCLC AdenocarcinomaSolid Tumoratamparib escalation levelsatamparib RP2D
brief summary
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
started
Feb 10, 2026
primary completion
Jul 31, 2028
completion
Jan 31, 2029
last updated
Jan 28, 2026
official title
A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol